Evicenter
MarkdownMedical informationP&T meetings
Obefazimod (ABX464)

Ulcerative colitis

Manufacturer
Abivax
Launch
Not announced
Last updated
173 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Interleukin-23 p19 inhibitors

8 evidence topics · 8 sources

ECCO 2026 guideline: recommendations and risankizumab trial results

“We recommend treatment with mirikizumab for the induction of remission in moderate-to-severe ulcerative colitis [strong recommendation, moderate certainty of evidence] [Agreement: 100%]” (opens the source at this quote in a new tab)

“We recommend treatment with risankizumab for the induction of remission in moderate-to-severe ulcerative colitis [strong recommendation, moderate certainty of evidence] [Agreement: 100%]” (opens the source at this quote in a new tab)

“We recommend treatment with guselkumab for the induction of remission in moderate-to-severe ulcerative colitis [strong recommendation, moderate certainty of evidence] [Agreement: 100%]” (opens the source at this quote in a new tab)

“At week 12, risankizumab significantly improved clinical remission rates compared with placebo (20.3% vs 6.2%, respectively; adjusted between-group difference [BGD]: 14.0% [95% CI: 10.0–18.0%]; P < .001).” (opens the source at this quote in a new tab)

“In the maintenance trial, each dose of risankizumab significantly improved clinical remission rates compared with placebo (40.2% for 180 mg risankizumab and 37.6% for 360 mg risankizumab vs 25.1% for placebo, BGD for 180 mg risankizumab vs placebo: 16.3% [95% CI: 6.1–26.6%]; P < .001)” (opens the source at this quote in a new tab)

“SC guselkumab is also effective for induction of remission in UC; this indication is supported by the efficacy and safety results from the ASTRO program.” (opens the source at this quote in a new tab)

“Data for IL-23 antagonist dose escalation are minimal and require further evidence before broader implementation.” (opens the source at this quote in a new tab)